MX2021001033A - Sales de amonio de 3-(3,5-dibromo-4-hidroxibencilideno)-5-indo-1,3 -dihidroindol-2-ona y sus usos. - Google Patents

Sales de amonio de 3-(3,5-dibromo-4-hidroxibencilideno)-5-indo-1,3 -dihidroindol-2-ona y sus usos.

Info

Publication number
MX2021001033A
MX2021001033A MX2021001033A MX2021001033A MX2021001033A MX 2021001033 A MX2021001033 A MX 2021001033A MX 2021001033 A MX2021001033 A MX 2021001033A MX 2021001033 A MX2021001033 A MX 2021001033A MX 2021001033 A MX2021001033 A MX 2021001033A
Authority
MX
Mexico
Prior art keywords
ammonium salts
hydroxybenzyliden
dihydroindol
indo
dibromo
Prior art date
Application number
MX2021001033A
Other languages
English (en)
Inventor
Tai-Lung Cha
Tai-Wei Ly
Yi-Ta Tsai
Sheng-Chieh Lin
Yun Yu
Original Assignee
Metagone Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagone Biotech Inc filed Critical Metagone Biotech Inc
Publication of MX2021001033A publication Critical patent/MX2021001033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se describe un compuesto de la fórmula (I), que es la sal de amonio de GW5074, (ver Fórmula) en donde R1, R2, y R3 son independientemente hidrógeno, alquilo, alquenilo, alquinilo, arilo, o heteroarilo; o R1, R2, R3 y el nitrógeno se toman juntos para formar un heterociclilo de 6 miembros; y el alquilo, el alquenilo, el alquinilo, el arilo, el heteroarilo, o el heterociclilo de 6 miembros está opcionalmente sustituido con por lo menos un sustituyente seleccionado del grupo que consiste en, -OH, -NH2, y -NRaRb, en donde Ra y Rb son independientemente alquilo, arilo, o heteroarilo. También se describe en el presente documento un kit farmacéutico para el tratamiento de cánceres. El kit farmacéutico incluye una primera formulación que comprende un inhibidor de c-Raf y un portador farmacéuticamente aceptable; y una segunda formulación que comprende el compuesto de fórmula (I) y un portador farmacéuticamente aceptable. Este documento también abarca un método para tratar a un sujeto que tiene cáncer. El método comprende: (: (a) detectar si las células cancerígenas del sujeto tienen fosforilación en la serina 308 de la proteína quinasa asociada con la muerte (DAPK); y (b) tratar el sujeto con base en la detección del paso (a) al administrar al sujeto (i) una cantidad eficaz de un inhibidor de c-Raf, y (ii) una cantidad eficaz del compuesto de la fórmula (I), cuando se detecta la fosforilación en la serina 308 de DAPK en las células cancerígenas.
MX2021001033A 2018-08-07 2019-07-24 Sales de amonio de 3-(3,5-dibromo-4-hidroxibencilideno)-5-indo-1,3 -dihidroindol-2-ona y sus usos. MX2021001033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862715296P 2018-08-07 2018-08-07
PCT/CN2019/097525 WO2020029799A1 (en) 2018-08-07 2019-07-24 Ammonium salts of 3-(3,5-dibromo-4-hydroxybenzyliden)-5-indo-1,3-dihydroindol-2-one and uses thereof

Publications (1)

Publication Number Publication Date
MX2021001033A true MX2021001033A (es) 2021-07-07

Family

ID=69415380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001033A MX2021001033A (es) 2018-08-07 2019-07-24 Sales de amonio de 3-(3,5-dibromo-4-hidroxibencilideno)-5-indo-1,3 -dihidroindol-2-ona y sus usos.

Country Status (12)

Country Link
US (1) US11304930B2 (es)
EP (1) EP3833656A4 (es)
JP (1) JP7201273B2 (es)
KR (1) KR20210022695A (es)
CN (1) CN112771023B (es)
AU (1) AU2019319448B2 (es)
CA (1) CA3106060A1 (es)
IL (1) IL280490A (es)
MX (1) MX2021001033A (es)
PH (1) PH12021550118A1 (es)
TW (1) TWI718608B (es)
WO (1) WO2020029799A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP3091009B1 (en) 2011-10-25 2018-08-29 Janssen Pharmaceutica NV Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
US20140357676A1 (en) * 2013-05-28 2014-12-04 National Defense Medical Center Pharmaceutical compositions and methods for treating cancer and biomarkers for drug screening
WO2016078044A1 (zh) * 2014-11-19 2016-05-26 国防医学院 用于治疗癌症的药物组合物以及筛选药物的生物标记

Also Published As

Publication number Publication date
TW202019879A (zh) 2020-06-01
CN112771023A (zh) 2021-05-07
TWI718608B (zh) 2021-02-11
KR20210022695A (ko) 2021-03-03
AU2019319448A1 (en) 2021-02-04
EP3833656A4 (en) 2022-05-11
JP2021533117A (ja) 2021-12-02
CN112771023B (zh) 2024-04-09
IL280490A (en) 2021-03-25
PH12021550118A1 (en) 2021-09-27
US20210283103A1 (en) 2021-09-16
WO2020029799A1 (en) 2020-02-13
AU2019319448B2 (en) 2022-06-02
US11304930B2 (en) 2022-04-19
CA3106060A1 (en) 2020-02-13
EP3833656A1 (en) 2021-06-16
JP7201273B2 (ja) 2023-01-10

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2018003472A (es) Moduladores de la expresion de kras.
PH12020550936A1 (en) Combination drug including tlr7 agonist
MY198605A (en) Maytansinoid derivatives conjugates thereof, and methods of use
NZ754865A (en) Combination therapy for the treatment of cancer
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
PH12021550558A1 (en) Modulators of pnpla3 expression
PH12019502174A1 (en) Modulators of pcsk9 expression
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
PH12020551995A1 (en) Modulator of apol1 expression
PH12021551053A1 (en) Modulators of irf5 expression
WO2020127259A3 (en) Materials for electronic devices
PH12021551138A1 (en) Application of chidamide in combination with r-chop, and drug combination
MX2020001557A (es) Combinaciones herbicidas sinergicas.
CO2020008769A2 (es) Moduladores de la expresión dnm2
JOP20210107A1 (ar) مضمنات التعبير عن foxp3
PH12021550118A1 (en) Ammonium salts of 3-(3,5-dibromo-4-hydroxybenzyliden)-5-indo-1,3-dihydroindol-2-one and uses thereof
MX2020010721A (es) Moduladores de la expresion de ezh2.
MX2020003554A (es) Moduladores de la expresion de enac.
MX2020010424A (es) Comprimido o composicion que contiene n-acil etanolamina y cannabinoides.
MX2021013908A (es) Tratamiento para el cáncer.
AU201616222S (en) Wood Stacker
UA91586U (uk) Спосіб лікування больової чутливості при невралгії трійчастого нерва
MX2015004799A (es) Solucion via cutanea para facilitar regeneracion de tejidos blandos en un ambiente aseptico y alcalino.